KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial.

Seung Wook Lee, Seung Hwan Lee, Jae Heon Kim, Joon Hwa Noh, Jun Ho Lee, U-Syn Ha, Cheol Young Oh, Taek Won Kang, Gyeongseop Lee, Sangchul Lee, Deok Hyun Han, Jun Hyun Han, Sang Hoon Song, Hyun Jun Park, Byung Ha Chung, Gyeong Eun Min, In Gab Jeong, Kyung Hyun Moon, Won Tae Kim, Ji Youl Lee, Choung-Soo Kim

BJU Int 137(4) 698-707

PMID41667130
PMCIDPMC12962842
DOI10.1111/bju.70163
发表日期2026-02-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:生活质量量表图;Fig. 3:森林图/亚组分析图。
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of a fixed-dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom Score (IPSS) and randomised (1:1:1) to receive FDC dutasteride 0.5 mg/tadalafil 5 mg (FDC 0.5/5 mg), dutasteride 0.5 mg, or tadalafil 5 mg for 48 weeks. The primary endpoint was the change in total IPSS from baseline to Week 48. Efficacy and safety were assessed at 4, 12, 24, 36, and 48 weeks. RESULTS: In total, 619 patients were analysed for efficacy. The least squares (LS) mean (standard error [se]) change in total IPSS at 48 weeks from baseline was -9.49 (0.37) for the FDC 0.5/5 mg group vs -4.40 (0.37) for dutasteride 0.5 mg group (LS mean difference [LSMD] -5.09, 95% confidence interval [CI] -6.13 to -4.50; P < 0.001), and -9.53 (0.36) for the FDC 0.5/5 mg group vs -4.24 (0.37) for tadalafil 5 mg group (LSMD -5.29, 95% CI -6.30 to -4.27; P < 0.001). The FDC 0.5/5 mg group demonstrated the most pronounced improvement in quality of life. Although the maximum urinary flow rate and post-void residual volume improved in all groups, differences were not statistically significant. In the comparison between the FDC 0.5/5 mg and dutasteride 0.5 mg groups, the LSMD (95% CI) of change from baseline to Week 48 in the international index of erectile function - erectile function (IIEF - EF) total score was 4.03 (2.35 to -5.71) (P < 0.05). Among the 655 patients analysed for safety, treatment-emergent adverse events occurred in 32.88% (FDC 0.5/5 mg) vs 21.20% (dutasteride 0.5 mg) and 26.48% (tadalafil 5 mg), with few serious adverse events observed. CONCLUSIONS: The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study disposition. Patient Consolidated Standards of Reporting Trials (CONSORT) diagram.
非 KM Figure
Fig. 2( A ) Change from baseline in obstructive IPSS, irritative IPSS and QoL at Week 48. ( B ) Change from baseline in Q max , voiding volume, PVR, PSA level, and PV at Week 48. ( C ) Changes from baseline in IIEF ‐ EF total score, SEP Question 2 success rates, SEP Question 3 success rates at Week 48.
非 KM Figure
Fig. 3Forest plots of subgroup analyses of change in total IPSS at Week 48. ( A ) FDC 0.5/5 mg vs dutasteride 0.5 mg ( B ) FDC 0.5/5 mg vs tadalafil 5 mg ( C ) dutasteride 0.5 mg vs tadalafil 5 mg. Effects are mean differences (treatment − comparator) with 95% CIs. Overall P values are shown next to ‘Overall’; subgroup header P values are shown for each subgroup.
非 KM Figure